A new option for assisted reproductive technology (ART) is now available in Ireland: Lubion PFS, a licensed subcutaneous progesterone treatment. The announcement, made on March 20, 2026, by IBSA UK & Ireland, addresses a demand for alternative progesterone delivery methods for women undergoing IVF who are unable to use or tolerate traditional vaginal preparations. This marks IBSA’s first directly supplied fertility medicine in the country.
Progesterone plays a crucial role in supporting the luteal phase of the menstrual cycle, which is essential for successful implantation of a fertilized egg. Subcutaneous administration offers a convenient alternative to vaginal progesterone, and Lubion PFS provides a licensed formulation specifically designed for this purpose. The availability of this treatment aims to improve access to care and provide more options for patients, and clinicians.
Expanding Access to Progesterone Support
Currently, progesterone is a vital component of many ART protocols. It helps prepare the lining of the womb to receive a fertilized egg and supports early pregnancy. However, not all women can comfortably or effectively use vaginal progesterone, which has historically been the most common method of administration. Lubion PFS offers a solution for these patients, providing a licensed, ready-to-use formulation delivered via a once-daily subcutaneous injection.
Melissa Mark, Nurse Manager at Therapie Fertility, highlighted the benefits of having IBSA’s support for Lubion PFS. “We have incorporated Lubion® into IVF treatment plans in Ireland for many years, and having IBSA’s support now gives us strong reassurance and confidence in its continued supply and availability for our patients,” Mark said. “Lubion® provides an essential, convenient progesterone option for women who cannot tolerate vaginal preparations, and its subcutaneous formulation facilitates comfortable administration.”
What is Lubion PFS?
Lubion PFS (progesterone 25 mg) is an aqueous solution for subcutaneous injection supplied in a pre-filled syringe. It contains the active ingredient progesterone, a naturally occurring female sex hormone. According to IBSA Fertility, progesterone works on the lining of the womb to help a woman become and stay pregnant. The treatment is specifically indicated for women undergoing ART who cannot use or tolerate vaginal progesterone preparations.
The product’s key features include being the first and only licensed aqueous progesterone for subcutaneous injection in Ireland. This licensing provides Irish IVF clinics with a formal, supported access route to the treatment, ensuring consistent supply and quality.
Understanding the Indications and Contraindications
Lubion PFS is intended for use under the guidance of a healthcare professional as part of an ART program. It’s crucial for patients to follow their clinic’s specific dosage instructions, as the dose may be adjusted throughout the treatment course.
However, Lubion PFS is not suitable for everyone. Individuals should not use the medication if they have a known allergy to progesterone or any of its ingredients, are experiencing unexplained vaginal bleeding, have had a recent miscarriage with suspected retained tissue, have a history of ectopic pregnancy, or have severe liver problems. It is also contraindicated for those with known or suspected breast cancer or cancer of the reproductive tract, a history of blood clots, or porphyria disorder. A complete list of contraindications can be found in the patient information leaflet.
The Role of Subcutaneous Progesterone in ART
The subcutaneous route of progesterone administration offers several advantages. It bypasses potential issues with vaginal absorption and discomfort, providing a more reliable and consistent delivery of the hormone. This is particularly important in ART, where precise hormone levels are critical for successful outcomes. The availability of a licensed subcutaneous progesterone option like Lubion PFS expands the toolkit available to fertility specialists in Ireland, allowing them to tailor treatment plans to individual patient needs.
IBSA’s announcement signals a commitment to providing innovative fertility solutions and improving access to care for patients in Ireland. The company plans to continue supporting clinics and patients with educational resources and ongoing supply of Lubion PFS.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
The next step for patients interested in Lubion PFS is to discuss its suitability with their fertility clinic. Clinics now have a formal, supported route to access this treatment, and can determine if it is the right option for individual circumstances. For more information, patients can refer to the patient information leaflet and frequently asked questions available through IBSA Fertility.
Have you or someone you know benefited from advancements in ART? Share your experiences and thoughts in the comments below.
